Drugs / Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
last change Jan 2015 re-read 2 minutes ago

Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013

Vaccine

Developed for
influenza
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID)

Trials 1 · a red edge is where a trial was stopped

20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01942265 Sep 2013 → Jan 2015 influenza National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01942265
Modality Vaccine “monovalent influenza A/H7N9 virus vaccineNCT01942265
Route Intramuscular “delivered intramuscularly approximately 21 days apart” NCT01942265